BG103152A - Адамантилови производни индуциращи апоптозис и тяхното приложение като анти-канцерогенни средства - Google Patents

Адамантилови производни индуциращи апоптозис и тяхното приложение като анти-канцерогенни средства

Info

Publication number
BG103152A
BG103152A BG103152A BG10315299A BG103152A BG 103152 A BG103152 A BG 103152A BG 103152 A BG103152 A BG 103152A BG 10315299 A BG10315299 A BG 10315299A BG 103152 A BG103152 A BG 103152A
Authority
BG
Bulgaria
Prior art keywords
cancer
adamantyl
derivative
treatment
catinerogeneans
Prior art date
Application number
BG103152A
Other languages
English (en)
Inventor
Magnus Pfahl
Xian-Ping Lu
Darryl Rideout
Hongyue Zhang
Original Assignee
Galderma Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research & Development filed Critical Galderma Research & Development
Publication of BG103152A publication Critical patent/BG103152A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cosmetics (AREA)

Abstract

Изобретението се отнася до специфичен адамантил или производна адамантилова група, съдържащи се в ретеноидни съединения, индуциращи апоптозис в канцерогенните клетки. Те са ефективни при лечението намного злокачествени и твърди тумори, по-специално андрогеннезависим рак на простатата, рак на кожата, карциноми на панкреаса, рак на дебелото черво, меланома, рак на яйчниците, рак на черния дроб, алвеолен рак, бронхиален рак, карцином на маточната шийка, рак на мозъка, рак на пикочния мехур, рак нагърдата, невробластома/глиобластома и левкемия. Изобретението се отнася и до нови адамантилови съединения или производни с адамантилова група, които са активни средства при лечението или предпазването от каритинизиращи разстройства, други дерматологични състояния и други заболявания.
BG103152A 1996-07-08 1999-02-05 Адамантилови производни индуциращи апоптозис и тяхното приложение като анти-канцерогенни средства BG103152A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2128596P 1996-07-08 1996-07-08
PCT/US1997/011564 WO1998001132A1 (en) 1996-07-08 1997-07-08 Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents

Publications (1)

Publication Number Publication Date
BG103152A true BG103152A (bg) 1999-09-30

Family

ID=21803357

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103152A BG103152A (bg) 1996-07-08 1999-02-05 Адамантилови производни индуциращи апоптозис и тяхното приложение като анти-канцерогенни средства

Country Status (21)

Country Link
US (1) US6127415A (bg)
EP (1) EP0920312B1 (bg)
JP (1) JP2000515506A (bg)
KR (1) KR20000023626A (bg)
CN (1) CN1279902C (bg)
AT (1) ATE284213T1 (bg)
AU (1) AU719311B2 (bg)
BG (1) BG103152A (bg)
BR (1) BR9710255A (bg)
CA (1) CA2259936C (bg)
CZ (1) CZ3499A3 (bg)
DE (1) DE69731885T2 (bg)
ES (1) ES2231877T3 (bg)
HU (1) HUP9903834A3 (bg)
IL (1) IL127946A0 (bg)
NO (1) NO990066L (bg)
NZ (1) NZ333800A (bg)
PT (1) PT920312E (bg)
RU (1) RU2209626C2 (bg)
TR (1) TR199900684T2 (bg)
WO (1) WO1998001132A1 (bg)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462064B1 (en) * 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
FR2759292B1 (fr) * 1997-02-10 2000-08-11 Cird Galderma Utilisation de retinoides en tant qu'agents induisant la pigmentation
FR2779723B1 (fr) * 1998-06-12 2000-07-13 Cird Galderma Composes biaryles heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
AU6949900A (en) * 1999-08-31 2001-03-26 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
PL373912A1 (en) 2001-03-07 2005-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2002072543A2 (en) * 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
CA2340824A1 (en) * 2001-03-14 2002-09-14 Ibm Canada Limited-Ibm Canada Limitee Method and system for application behavior analysis
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
KR100706589B1 (ko) * 2001-10-31 2007-04-11 에프. 호프만-라 로슈 아게 헤테로고리 레티노이드 화합물
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
CA2468745A1 (en) 2001-11-30 2003-06-12 The Burnham Institute Induction of apoptosis in cancer cells
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7449480B2 (en) * 2002-05-14 2008-11-11 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
WO2003097855A2 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
US20040156799A1 (en) * 2002-06-04 2004-08-12 Zigang Dong Cancer treatment method and compositions
US6864264B1 (en) * 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
RU2005135850A (ru) * 2003-04-18 2006-06-10 Инсайт Сан Диего Инкорпорейтед (Us) Замещенные изохромановые соединения для лечения метаболических расстройств, рака и другие заболеваний
RU2257894C1 (ru) * 2003-12-03 2005-08-10 Государственный научный центр-Институт биофизики Противоопухолевое средство бензамид
WO2007063522A1 (en) * 2005-12-02 2007-06-07 Finorga Sas Process for the preparation of aromatic derivatives of 1-adamantane
US9486467B2 (en) * 2006-06-12 2016-11-08 Ramot At Tel-Aviv University Ltd. Method of treating colorectal cancer that expresses a mutated APC gene by administering erythromycin or tylosin
PT2125697T (pt) 2007-01-15 2016-10-18 Yu Chongxi Pró-fármacos solúveis em água positivamente carregados de retinóides e compostos tipo retinóide com taxas de penetração na pele muito altas
EP2532643A1 (en) 2007-06-08 2012-12-12 MannKind Corporation IRE-1A Inhibitors
RU2360692C1 (ru) * 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, стимулирующее апоптоз клеток лейкемии человека
CN102241678B (zh) * 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
KR101604053B1 (ko) * 2011-08-05 2016-03-16 (주)아모레퍼시픽 신규 벤조산아미드 화합물
CN103923107B (zh) * 2014-04-11 2016-06-01 安徽师范大学 金刚烷基吡啶配合物、中间体及其制备方法和应用
CN103936770B (zh) * 2014-04-11 2016-06-01 安徽师范大学 金刚烷基吡啶酰胺配合物、中间体及其制备方法和应用
CN103936771B (zh) * 2014-04-11 2016-06-01 安徽师范大学 金刚烷基吡啶甲酰胺配合物、中间体及其制备方法和应用
WO2017053778A1 (en) 2015-09-25 2017-03-30 Fuchs Helen Burgwyn Antibacterial and antifungal compounds
US20170181988A1 (en) * 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer
EP3301085A1 (en) * 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
WO2018213609A1 (en) * 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
IT201900003343A1 (it) 2019-03-07 2020-09-07 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
AU2020241258B2 (en) * 2019-03-15 2025-09-11 The General Hospital Corporation Novel small molecule inhibitors of TEAD transcription factors
CN112341406B (zh) * 2020-11-18 2023-02-10 韶远科技（上海)有限公司 反式-4-[4-(3-甲氧基-4-硝基苯基)-1-哌嗪基]金刚烷-1-醇合成方法
IT202000029906A1 (it) 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi.
IT202000029912A1 (it) 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
IT202000029882A1 (it) 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU182048B (en) * 1978-04-14 1983-12-28 Sumitomo Chemical Co Process for preparing brendane derivatives and brendane analogues
DE3026579A1 (de) * 1980-07-14 1982-02-11 Kali-Chemie Pharma Gmbh, 3000 Hannover 2,9-dioxatricyclo (4,3,1,o(pfeil hoch)3,7(pfeil hoch)) decane
LU85544A1 (fr) * 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques
US5098929A (en) * 1985-07-30 1992-03-24 The Wellcome Foundation Limited Pesticidal compounds
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
US5770382A (en) * 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
JP2000506489A (ja) * 1995-07-17 2000-05-30 センタ インタナショナル ドゥ リシェルシェ デルマトロジーク セ イ エール デ ガルデルマ Ａｈｐｎを用いる癌の治療方法
FR2741876B1 (fr) * 1995-12-01 1998-01-09 Cird Galderma Composes biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US5888432A (en) * 1996-12-23 1999-03-30 Corning Incorporated 2-Adamantyl benzopyrans the compositions and (co)polymer matrices containing them
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity

Also Published As

Publication number Publication date
BR9710255A (pt) 1999-08-10
TR199900684T2 (xx) 1999-07-21
NO990066L (no) 1999-03-08
ES2231877T3 (es) 2005-05-16
EP0920312A4 (en) 2000-11-02
DE69731885D1 (de) 2005-01-13
IL127946A0 (en) 2000-02-17
CA2259936A1 (en) 1998-01-15
NO990066D0 (no) 1999-01-07
RU2209626C2 (ru) 2003-08-10
ATE284213T1 (de) 2004-12-15
HUP9903834A3 (en) 2001-02-28
KR20000023626A (ko) 2000-04-25
CN1230111A (zh) 1999-09-29
AU719311B2 (en) 2000-05-04
DE69731885T2 (de) 2005-12-22
EP0920312A1 (en) 1999-06-09
WO1998001132A1 (en) 1998-01-15
US6127415A (en) 2000-10-03
HUP9903834A2 (hu) 2000-05-28
CA2259936C (en) 2009-02-03
EP0920312B1 (en) 2004-12-08
AU3648597A (en) 1998-02-02
CZ3499A3 (cs) 1999-11-17
NZ333800A (en) 2000-08-25
PT920312E (pt) 2005-04-29
JP2000515506A (ja) 2000-11-21
CN1279902C (zh) 2006-10-18

Similar Documents

Publication Publication Date Title
BG103152A (bg) Адамантилови производни индуциращи апоптозис и тяхното приложение като анти-канцерогенни средства
DK1156798T3 (da) Felbamat-afledte forbindelser
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
BR9908222A (pt) Composições para regular a aparência da pele
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
DE60231439D1 (de) Mitotische kinesinhemmer
NO20032254D0 (no) Forbindelser for inhibering av ekspresjon av VACM-I
ATE292623T1 (de) 2-indolinonderivate als modulatoren der proteinkinase-ativität
EA200500170A1 (ru) Композиция на основе замещенных производных 1,3-дифенилпроп-2-ен-1-она, его получение и применения
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
DK57882A (da) Fremgangsmaade til fremstilling af tetrahydronaphthalen-og indanderivater
AR037343A1 (es) Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
DK1079851T3 (da) Anvendelse af anti-prolactinmidler til behandling af cancer
DE69734838D1 (de) Verwendung von zinksalzen der konjugierten linoleinsäuren zur behandlung von hautkrankheiten
WO2002039953A3 (en) Texaphyrin coordination compounds and uses thereof
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.
ECSP003590A (es) Compuestos calcioliticos
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
TR199700694T1 (xx) D vitamini t�revlerinin dermotolojik kullan�m�.
DE60113418D1 (de) Anti-karzinogene aktivität von aus der lakritzenwurzel isolierten hydroxylierten chalcon-verbindungen
DE69912477D1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
UA19045A (uk) Спосіб одержаhhя похідhих стильбеhу
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри